Two Sigma Investments LP bought a new position in shares of CRISPR Therapeutics (NASDAQ:CRSP) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 45,974 shares of the company’s stock, valued at approximately $1,079,000. Two Sigma Investments LP owned approximately 0.10% of CRISPR Therapeutics as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also modified their holdings of CRSP. Creative Planning acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter worth about $243,000. Vanguard Group Inc. acquired a new stake in shares of CRISPR Therapeutics during the 2nd quarter worth about $273,000. Bank of New York Mellon Corp acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth about $288,000. Wells Fargo & Company MN raised its position in shares of CRISPR Therapeutics by 129.8% during the 3rd quarter. Wells Fargo & Company MN now owns 18,352 shares of the company’s stock worth $328,000 after acquiring an additional 10,365 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new position in CRISPR Therapeutics during the third quarter worth approximately $344,000. 26.50% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have commented on the company. Piper Jaffray reaffirmed a “buy” rating and set a $22.75 price target (down previously from $39.00) on shares of CRISPR Therapeutics in a research report on Wednesday, January 10th. ValuEngine raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Oppenheimer reaffirmed a “hold” rating on shares of CRISPR Therapeutics in a research report on Thursday, December 21st. SunTrust Banks reaffirmed a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a research report on Friday, March 9th. Finally, BidaskClub raised CRISPR Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $63.95.
NASDAQ:CRSP opened at $51.77 on Friday. The company has a market capitalization of $2,479.09, a PE ratio of -30.27 and a beta of 3.56. CRISPR Therapeutics has a 12-month low of $13.50 and a 12-month high of $61.24.
In other news, insider Tyler Dylan-Hyde sold 66,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $28.03, for a total value of $1,849,980.00. Following the transaction, the insider now owns 25,204 shares of the company’s stock, valued at $706,468.12. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 39.98% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Two Sigma Investments LP Invests $1.08 Million in CRISPR Therapeutics (CRSP)” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://ledgergazette.com/2018/04/15/45974-shares-in-crispr-therapeutics-crsp-purchased-by-two-sigma-investments-lp.html.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.